Filter posts

AMP v. Myriad: BIO Statement on Federal Circuit (Re)Decision

BIO released the following statement on the Federal Circuit’s decision in the AMP v. Myriad …

Technology Transfer Impact? Senator Bayh Informs on IPWatchdog

IPWatchdog published an article by former Senator Birch Bayh highlighting a BIO commissioned study showing …

USPTO Blogpost Brings Mayo Down to Earth

The United States Patent and Trademark Office Director David Kappos posted a blogpost called “Some …

Developments in the creation of a single EU Patent System stalled – Again.

By Catherine McLoughlin, specialist solicitor for Biotech and Pharmaceutical Companies, Pannone LLP After 40 years …

The U.S. Government’s Position in ACLU v. Myriad Genetics

Hans Sauer, BIO’s Deputy General Counsel for Intellectual Property, comments on  the Department of Justice’s brief …

Patent Evergreening in India: Response from the Other Side

Thank you Adriana for commenting on my article Patent “Ever-Greening”: Novartis Confronts Patent Myth in …

Seed Patents: How Innovation May Get Lost in the Grain Elevator

The Bowman v. Monsanto case currently on petition for a writ of certiorari to the …

Prior User Rights and Trade Secrets

By Joe Allen, President, Allen and Associates One theme of the day is the cloud …

Recent Developments in Patentability: Prometheus and Myriad

By Joe Allen, President, Allen and Associates Recent Developments in Patentability: Prometheus and Myriad at …

From Bench to Bedside in a Bioeconomy

By Joe Allen, President, Allen and Associates It’s a sign of a well crafted program …